[1].Paul Tanswell, et al. Pharmacokinetics and Pharmacodynamics of Tenecteplase in Fibrinolytic Therapy of Acute Myocardial Infarction. Clin Pharmacokinet. 2002;41(15):1229-45.

[2].Menon B K, Buck B H, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial[J]. Lancet, 2022,400(10347):161-169.

[3].Meng X, Li S, Dai H, et al. Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINALRandomized Clinical Trial[J]. JAMA, 2024,332(17):1437-1445.

[4].Shuya Li, Xiaolong Bao, Shijia Yan, Yongjun Wang.Tenecteplase versus alteplase for patients with minor acute ischemic stroke (AIS): An analysis of the ORIGINAL study[C].2025 European Stroke Organisation Conference(ESOC);Presentation ID 118,21–23 May 2025, Helsinki,Finland.

[5].Parsons M W, Yogendrakumar V, Churilov L, et al. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4.5 h of onset of ischaemic stroke (TASTE): a  multicentre, randomised, controlled, phase 3 non-inferiority trial[J]. Lancet Neurol, 2024,23(8):775-786.

[6].Muir K W, Ford G A, Ford I, et al. Tenecteplase versus alteplase for acute stroke within 4.5 h of onset (ATTEST-2):a randomised, parallel group, open-label trial[J]. Lancet Neurol, 2024,23(11):1087-1096.

[7].中国卒中学会急性缺血性卒中再灌注治疗指南2024 [J]. 中国卒中杂志, 2024, 19 (12): 1460-1478.